Anavex Life Sciences Corp (AVXL)

[falconer66a]

Blarcamesine First as an Insomnia Treatment?

Could it be that Anavex is now pressing for blarcamesine as a treatment solely for the agitation and insomnia of Alzheimer’s, instead of a treatment for the cognition pathologies of that disease? Might that approach be an easier route to commercialization of the drug?

The vast majority of those suffering with Alzheimer’s have agitation or sleep difficulties consequent to the onset of this CNS disease. The market is gigantic. And, of course, those being able to take blarcamesine each day or two for their Alzheimer’s agitation or insomnia will incidentally also experience improved cognition. Two symptoms are targeted, agitation and insomnia, but a third symptom, cognitive decline, is incidentally reversed. Three for the price of two.